John D. Graham

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Matthew R. Sydes, John D. Graham et al. · The Lancet Oncology · 2007 · 908 citations

Medicine, Oncology, Radiation Oncology +17

Psychometric scores and persistence of irritable bowel after infectious diarrhoea

Kok‐Ann Gwee, John D. Graham, M W McKendrick et al. · The Lancet · 1996 · 464 citations

Medicine, Clinical Sciences, Infectious Diseases +14

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Gordana Jovic, Isabel Syndikus et al. · The Lancet Oncology · 2014 · 462 citations · Full text

Medicine, Oncology, Radiation Oncology +14